Peptron펩트론

Peptron's shares have fallen sharply over the past year as losses persist and recent news has been mixed.

Peptron is a Korean drug developer focused on sustained-release peptide drugs, with a GMP manufacturing facility and some revenue from materials, contract work and drug wholesale. Trailing twelve-month revenue is about ₩6.0B against an operating loss of about ₩25.7B, and the stock closed at ₩98,300, down 61.8% over one year. The data does not include a fair value estimate or analyst ratings.

What stands out

• Trailing revenue of about ₩6.0B is far below the operating loss of about ₩25.7B, giving an operating margin of roughly -428%.
• Borrowings of about ₩30.3B exceed cash of about ₩12.3B, and free cash flow over the period was about -₩29.5B.
• Shares are about 75% below their 52-week high of ₩392,500, and the price is ₩98,300 with a market cap of about ₩2.3T.
• Recent headlines report that Yuhan cancelled a ₩4B technology transfer contract, with Peptron receiving ₩1B instead.
• Foreign ownership fell from 5.2% to 5.0% over about 60 days, while retail investors were net sellers of about ₩12.8B over 20 days.

What to watch

• The half-year report filed in August 2026 and the next quarterly report will show whether losses and cash burn are narrowing.
• The corrected new facility investment filing and the August 2026 management-related filing have not been explained in the data; their details should be checked in the original filings.
• Recent news raises questions about clinical data and the technology transfer deal, so any further updates on trial results or partner agreements are worth following.